Radium-223, a first-in-class drug, travels directly to the site of bone metastases, where it emits alpha particles that exert an anti-tumor effect.
Interactive tool designed to educate patients and advocates about processes of drug development.
Canagliflozin blocks reabsorption of glucose in the kidney, increases glucose excretion, and lowers blood glucose levels.
Voluntary recall of anemia drug due to reports of anaphylaxis, including three deaths
Oxytrol is intended for use by those 18 and older.
In clinical trials, three patients treated with the hyponatremia drug experienced liver injury, which improved after discontinuing treatment.
Decreases body's production of testosterone.
The FDA has approved the Accu-Chek Combo system, a combination blood glucose meter and insulin pump that exchanges data using Bluetooth technology.
The FDA has approved Exparel (bupivacaine), a single-dose injection that provides post-surgical pain relief for up to 72 hours.
The FDA has approved denosumab (Prolia) as a treatment to increase bone mass in prostate cancer patients at high risk for fracture undergoing androgen deprivation therapy (ADT) and women with breast cancer at high risk for fracture who are receiving aromatase inhibitor therapy.
Bristol-Myers Squibb of Princeton, N.J., has received FDA approval to market Baraclude (entecavir) as a treatment for chronic hepatitis B (CHB) patients with evidence of decompensated liver disease.
Pradaxa (dabigatran etexilate) capsules have received FDA approval for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).
The FDA has ordered a halt to the marketing of unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of familial Mediterranean fever.
The FDA has proposed withdrawing approval of midodrine, a drug used to treat orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the medication have not been done, the agency announced.
Savient Pharmaceuticals, Inc., of East Brunswick, N.J., has received FDA clearance to market Krystexxa (pegloticase) as a treatment for chronic gout in adult patients refractory to conventional treatment.